<DOC>
	<DOCNO>NCT01021020</DOCNO>
	<brief_summary>This randomize , single dose , three-way crossover study evaluate bioequivalence two formulation colchicine , test product ( colchicine 0.6mg Mutual ) market combination product ( colchicine 0.5 mg probenecid 500 mg ) , administer fasting condition . It also determine bioavailability follow standard high-fat meal evaluate safety tolerability test product .</brief_summary>
	<brief_title>Bioequivalence Study Colchicine Tablets</brief_title>
	<detailed_description>This randomize , single dose , three-way crossover study evaluate bioequivalence two formulation colchicine , test product ( colchicine 0.6mg Mutual ) market combination product ( colchicine 0.5mg probenecid 500mg ) , administer fasting condition . It also determine bioavailability test product follow standard high-fat meal evaluate safety tolerability test product . Twenty-eight healthy , non-smoking , non-obese ( BMI 81-30 kg/m2 BW â‰¥110 lb ) , 18-45 year old , male female volunteer randomly assign crossover fashion receive one three dose regimen sequence washout period least 14 day dose period . After fast least 10 hour , subject receive either , one tablet colchicine 0.6 mg , one tablet colchicine 0.6 mg standardize high-fat , high-calorie breakfast 0.5mg/500mg colchicine/probenecid . All dos give 240mL room temperature water . Patients confine least 15 hour 24 hour dose daily outpatient visit follow 3 day . Blood drawn time sufficient adequately define concentration time curve dose regimen , compare assess bioequivalence reference test product effect food test product . Subjects also monitor adverse event throughout period .</detailed_description>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<criteria>Healthy adult volunteer , male female , 18 45 year age , inclusive , BMI 1830 kg/m2 , inclusive , weigh least 110 pound . Female volunteer must postmenopausal , surgically sterile , must commit abstain heterosexual contact use two method reliable birth control . Subjects report receive investigational drug within 28 day prior initiation dose . Subjects report presence history significant cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic , psychiatric disease . Subjects clinical lab result outside accepted reference range , reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . Subjects report history allergy colchicine relate drug , history clinically significant allergy include drug allergy . Subjects report clinically significant illness 4 week prior initiation dose . Subjects report history drug alcohol addiction abuse within past year , demonstrate positive drug abuse screen . Subjects currently use use tobacco product within 6 month prior dose administration . Subjects report donate great 150 ml blood within 28 day donate plasma within 14 day prior initiation dose . Subjects positive pregnancy screen , currently pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>fast</keyword>
	<keyword>fed</keyword>
	<keyword>healthy</keyword>
</DOC>